See Why NanoViricides, Inc. (NYSE: NNVC) is Topping Our Watchlist Right Now

*Sponsored Market Crux Announces NanoViricides, Inc. (NYSE: NNVC) As Its Next Potential Breakout Idea For Friday Morning! And Here’s Why… Recent Market Recognition Leads to An Approx. 45% Move in 12 Sessions. Surpassing Key Moving Averages, Indicating Positive Momentum Potential. Low Float, Less Than 14M Shares, Setting the Stage and Potential Significant Swings if Demand Begins to Shift. Focused on Solutions for Emerging Global Health Threats, Including New U.S. Vir-us. Expanding PipelineTargeting Vir-al Diseases Spread by Monkeys and Birds. Advancing into Phase 2 Trials and Pushing Forward with FDA Submission. Keep Reading to See Why We Have All Eyes on NanoViricides, Inc. (NYSE: NNVC) For This Morning… February 14, 2025 Dear Reader, We have less than 15 minutes to go before the bell rings. Have you considered looking at NanoViricides, Inc. (NYSE: NNVC) while it’s still early? Few industries offer the kind of life-changing potential seen in biotech and pharma, where one major breakthrough can elevate an under-the-radar company into a market leader overnight. But while most breakthroughs move the needle, some have the power to change the game entirely. That’s where NanoViricides, Inc. (NYSE: NNVC) comes in. In a world where global health threats like emerging vir-al out-breaks are escalating, NanoViricides is emerging as a pioneering force. Just days ago, a newly discovered vir-us in the U.S.—the Camp Hill vir-us—was linked to the deadly Nipah vir-us, sparking fears of a potential global pan-demic.  With its rapid mutation ability, this vir-us could become the next major health threat that crosses borders and puts populations at risk. And here’s the catch: We need solutions now, before it spreads further. NanoViricides, Inc. (NYSE: NNVC) is standing at the forefront of the battle against these emerging vir-al threats, offering innovative anti-vir-al technologies that could make all the difference.  They are developing cutting-edge treatments to combat vir-uses that others can't—including those spread by monkeys and birds.  NanoViricides, Inc. (NYSE: NNVC) Moves Approx. 45% in 12 Sessions, Trending Above Key Moving Averages… NanoViricides, Inc. (NYSE: NNVC) has moved approximately 45% over the last 12 sessions, from $1.03 on 1/28/2025 to $1.50 on 2/12/2025. During this period, (NNVC) has surpassed several key moving averages, including: 5-Day: $1.30 20-Day: $1.19 50-Day: $1.34 100-Day: $1.38 With the 200-Day moving average currently at $1.67, we have all eyes on NanoViricides, Inc. (NYSE: NNVC) right now.  With a market cap under $19M and fewer than 14M shares available to the public, NanoViricides, Inc. (NYSE: NNVC) operates with a tight structure that has historically fueled explosive growth potential.  This relatively low number of shares in the float can amplify movements, making it an even more intriguing company to watch. Keep reading to see why NanoViricides, Inc. (NYSE: NNVC) is topping our watchlist tomorrow morning… New Vir-al Out-break Raises Global Alarm—NanoViricides, Inc. (NYSE: NNVC) Aims to Combat Emerging Threats A new vir-al out-break has been declared a Public Health Emergency of International Concern by the World Health Organization.  A concerning variant, particularly dangerous for children, has emerged with heightened transmissibility and lethality.  Despite global attention, no approved treatment exists for this new vir-us, especially as it spreads beyond its origin. NanoViricides, Inc. (NYSE: NNVC) is working on an innovative solution, accelerating efforts to fight this out-break with its dr-ug, NV-387.  Preclinical studies show remarkable potential, and Phase 2 trials are on the horizon, focusing on patients affected by this new vir-us. Positioning Itself Against a Potential Pan-demic In addition to combating the current out-break, NanoViricides, Inc. (NYSE: NNVC) is addressing another looming threat: the rapidly mutating influenza vir-us transmitted by birds. The World Health Organization has raised concerns over genetic mutations in the vir-us that may render existing treatments ineffective.  Unlike conventional anti-vir-al dr-ugs that are vulnerable to mutations, NV-387 mimics host-side features the vir-us cannot alter, ensuring continued effectiveness even as the vir-us evolves. NV-387 has demonstrated broad-spectrum anti-vir-al properties, effective against vir-uses like influenza, RSV, and even orthopox vir-uses.  Early animal studies indicate superior performance over existing treatments like Tamiflu, making it a promising tool for tackling a wide range of vir-al diseases. Phase 2 Trials and FDA Progress NanoViricides, Inc. (NYSE: NNVC) is set to begin Phase 2 clinical trials for NV-387, focusing on treating patients infected by the new vir-us variant and expanding its use to respiratory vir-uses.  The trials will start with dose escalation, with results expected to inform the next steps toward FDA submission. With no current approved treatments for the new vir-al variant or the evolving H5N1 strain, NanoViricides, Inc. (NYSE: NNVC)’s research is more critical than ever.  The company is poised to be a key player in the fight against these global health threats, with NV-387 offering a potential cure and broad protection against emerging pathogens. With a market potential exceeding $10B, NanoViricides, Inc. (NYSE: NNVC) is advancing rapidly in the biotech space with groundbreaking anti-vir-al treatments.  The company is uniquely positioned for growth with its cutting-edge nanoviricide® technology, promising an impactful future in global health. NanoViricides, Inc. (NYSE: NNVC) Highlights  FDA Progress: Moving toward FDA submission with positive feedback on its NV-HHV-101 dr-ug candidate for herpes vir-uses. Innovative Technology: Nanoviricides can target vir-uses even as they mutate, offering broad protection against Vir-al infections. Manufacturing Facility: The company owns a cGMP-certified facility in Shelton, CT, allowing it to produce dr-ugs in-house, saving time and costs. HerpeCide™ Program: Focused on treating shingles, cold sores, and genital ulcers, with an estimated market size exceeding $10B. Diverse Pipeline: dr-ugs in development for influenza, HIV, Dengue, and Ebola with promising animal model results. Strong IP Portfolio: Exclusive patents for its TheraCour® technology, securing competitive market space. NanoViricides, Inc. (NYSE: NNVC) is positioned for growth with its breakthrough technology, broad pipeline, and in-house manufacturing, making it a key player in the fight against Vir-al diseases. 7 Reasons Why NanoViricides, Inc. (NYSE: NNVC) is Topping Our Watchlist This Morning… 1. Recent Market Recognition: Over the past 12 sessions, NanoViricides, Inc. (NYSE: NNVC) has moved approximately 45%, from $1.03 on 1/28/2025 to $1.50 on 2/12/2025. 2. Surpassing Key Technical Levels: NanoViricides, Inc. (NYSE: NNVC) has surpassed key moving averages, including the 5-Day, 20-Day, 50-Day, and 100-Day, suggesting positive market sentiment and momentum. 3. Low Float: With a market cap under $19M and fewer than 14M shares listed in the float, NanoViricides, Inc. (NYSE: NNVC) operates with a tight structure, which could have the potential to showcase significant swings if demand begins to shift 4. Cutting-Edge Antivir-al Technology: NanoViricides, Inc. (NYSE: NNVC) is developing its proprietary nanoviricide® technology, which targets and dismantles vir-uses, even as they mutate, offering broader and more durable protection compared to traditional anti-vir-al methods. 5. Focused on Emerging Global Health Threats: NanoViricides, Inc. (NYSE: NNVC) is actively working on solutions for some of the most pressing vir-al out-breaks, including a newly discovered vir-us in the U.S., and is positioned to address further global health risks related to rapidly mutating vir-uses. 6. Expanding Pipeline: In addition to NV-387, NanoViricides, Inc. (NYSE: NNVC) has a robust pipeline targeting a variety of vir-al diseases, including those spread by monkeys and birds, further increasing its potential impact. 7. Advancing Clinical Trials and FDA Submission: NanoViricides, Inc. (NYSE: NNVC) is advancing NV-387 into Phase 2 clinical trials, with plans for broader use against respiratory and animal-origin vir-uses. The company is also progressing toward FDA submission for its NV-HHV-101 herpes treatment, with positive feedback received from pre-IND studies. Consider Adding NanoViricides, Inc. (NYSE: NNVC) To Your Radar This Morning—While It’s Still Early… If you haven’t yet taken notice, now’s the time to take a look at NanoViricides, Inc. (NYSE: NNVC). With a recent move of approx. 45% in just 12 sessions, (NNVC) has been catching plenty of attention, and it's not just some fluke.  With technicals pointing in the right direction, a market cap under $19M, and fewer than 14M shares listed in the float, NanoViricides, Inc. (NYSE: NNVC) is one little-known company to keep an eye on it. Add in the fact that they’re advancing Phase 2 trials for NV-387 and getting positive feedback from the FDA for NV-HHV-101, and you’ve got the makings of a biotech company that could disrupt the status quo. We’ll have all eyes on (NNVC) this morning.  Consider taking a look at (NNVC) before the bell rings—we have less than 15 minutes to go.  Watch for my next update—it could be here very soon. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 02/13/2025 and ending on 02/14/2025 to publicly disseminate information about (NNVC:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices.  Neither Headline Media LLC, TD Media LLC and their members own shares of (NNVC:US). Please see important disclosure information here: https://marketcrux.com/disclosure/nnvc/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice